CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $531 | -21.3% | 11,707 | -2.6% | 0.00% | 0.0% |
| Q2 2023 | $675 | +19.9% | 12,015 | -3.5% | 0.00% | 0.0% |
| Q1 2023 | $563 | +8.5% | 12,449 | -2.4% | 0.00% | 0.0% |
| Q4 2022 | $519 | -99.9% | 12,755 | -17.5% | 0.00% | -50.0% |
| Q3 2022 | $1,010,000 | -3.0% | 15,457 | -9.8% | 0.00% | -20.0% |
| Q2 2022 | $1,041,000 | -5.4% | 17,133 | -2.3% | 0.01% | +25.0% |
| Q1 2022 | $1,100,000 | -16.8% | 17,535 | +0.5% | 0.00% | -20.0% |
| Q4 2021 | $1,322,000 | -38.3% | 17,452 | -8.8% | 0.01% | -44.4% |
| Q3 2021 | $2,141,000 | +31.9% | 19,128 | +90.8% | 0.01% | +12.5% |
| Q2 2021 | $1,623,000 | – | 10,024 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |